TCM
VIR icon

Tekla Capital Management’s Vir Biotechnology VIR Stock Holding History

Tekla Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-81,400
Closed -$3.54M – 181
2021
Q3 		$3.54M Hold
81,400
– – 0.11% 120
2021
Q2 		$3.85M Hold
81,400
– – 0.13% 131
2021
Q1 		$4.17M Buy
+81,400
New +$4.39M 0.14% 128

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Tekla Capital Management's VIR Position: Q4 2021 in Review

Tekla Capital Management sold out of Vir Biotechnology (VIR) in Q4 2021, closing a stake of 81,400 shares — an estimated $3.54M sold.

Tekla Capital Management first reported a position in VIR in Q1 2021 and held it in 3 quarters. The position peaked at $4.17M in Q1 2021. 210 funds tracked by Wall St. Rank hold VIR as of Q4 2021.

  • Tekla Capital Management reported no remaining Vir Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Tekla Capital Management sold 81,400 Vir Biotechnology shares in Q4 2021, an estimated $3.54M.
  • Tekla Capital Management first reported a position in Vir Biotechnology in Q1 2021 and held it in 3 quarters.
  • Tekla Capital Management's Vir Biotechnology position peaked at $4.17M in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2021.

Based on Tekla Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.